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Abstract
Background—Diabetes mellitus and its complications are a large and increasing burden for 
health care worldwide. Reduced pulmonary function has been observed in diabetes (both type 1 
and type 2), and this reduction is thought to occur prior to diagnosis. Other measures of pulmonary 
health are associated with diabetes, including lower exercise tolerance, greater dyspnea, lower 
quality of life (as measured by the St. George’s Respiratory Questionaire [SGRQ]) and 
susceptibility to lung infection and these measures may also predate diabetes diagnosis.
Methods—We examined 7080 participants in the COPD Genetic Epidemiology (COPDGene) 
study who did not report diabetes at their baseline visit and who provided health status updates 
during 4.2 years of longitudinal follow-up (LFU). We used Cox proportional hazards modeling, 
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censoring participants at final LFU contact, reported mortality or report of incident diabetes to 
model predictors of diabetes. These models were constructed using known risk factors as well as 
proposed markers related to pulmonary health, forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC), FEV1/FVC, respiratory exacerbations (RE), 6-minute walk distance 
(6MWD), pulmonary associated quality of life (as measured by the SGRQ), corticosteroid use, 
chronic bronchitis and dyspnea.
Results—Over 21,519 person years of follow-up, 392 of 7080 participants reported incident 
diabetes which was associated with expected predictors; increased body mass index (BMI), high 
blood pressure, high cholesterol and current smoking status. Age, gender and accumulated 
smoking exposure were not associated with incident diabetes. Additionally, preserved ratio with 
impaired spirometry (PRISm) pattern pulmonary function, reduced 6MWD and any report of 
serious pulmonary events were associated with incident diabetes.
Conclusions—This cluster of pulmonary indicators may aid clinicians in identifying and 
treating patients with pre- or undiagnosed diabetes.
Keywords
chronic obstructive pulmonary disease; COPD; diabetes; pulmonary predictors
Background
Diabetes and its complications are a large and increasing burden for health care worldwide. 
Reduced pulmonary function has been observed in type 2 diabetes1–5 and this reduction is 
thought to occur prior to diagnosis.6–9 Other measures of pulmonary health are associated 
with diabetes, including lower exercise tolerance,10 greater dyspnea and lower pulmonary 
associated quality of life (as measured by the St. George’s Respiratory Questionaire 
[SGRQ])11 and these measures may also predate diabetes diagnosis. Hyperglycemia has 
been shown to increase glucose in airway surface liquid (ASL)12 promoting bacterial 
growth13 which may lead to increased pulmonary associated adverse events.14,15 These 
events can result in emergency room visits or hospitalizations and poor outcomes of those 
hospitalizations.16 Hyperglycemia can also reduce the effectiveness of the innate immune 
system of the lung by reducing surfactant protein-D17 which may be associated with lung 
infection and reduced diffusing lung capacity.18,19 Smoking has also been shown to be an 
independent predictor of type 2 diabetes20 and quitting smoking has been shown to reduce 
the risk of metabolic syndrome.21 Pulmonary risk factors beyond smoking such as reduced 
pulmonary function, reduced exercise capacity, increased dyspnea and increased propensity 
for lung infection may be associated with the development of diabetes.
This study used data collected at the baseline visit and during longitudinal follow-up of a 
large cohort of smokers (>10 pack years smoking history) from the Genetic Epidemiology of 
Chronic Obstructive Pulmonary Disease (COPDGene) study to investigate factors preceding 
diabetes diagnosis. Known diabetes risk factors include obesity, male gender, increased age, 
hypertension, high cholesterol and steroid use and potential diabetes risk factors include 
reduced measures of pulmonary function (forced expiratory volume in 1 second [FEV1], 
forced vital capacity [FVC] and their ratio), reduced 6-minute walk distance (6MWD), poor 
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pulmonary associated quality of life measured by SGRQ, increased modified Medical 
Research Council (mMRC) dyspnea scale, chronic bronchitis, chronic obstructive 
pulmonary disease (COPD) and reported respiratory infection.
Methods
The COPDGene study has been described in detail elsewhere.22 Briefly, COPDGene is a 
case control study designed to identify genetic risk factors for COPD in a biracial population 
of non-Hispanic white (~2/3) and African American (~1/3) smokers (current and former) 
with at least 10 pack years history of cigarette use. COPDGene participants were between 45 
and 80 years old at initial contact, spanning COPD disease severity as measured by the 
Global initiative for chronic Obstructive Lung Disease (GOLD) criteria23 and include 
10,192 participants from 21 clinical centers. COPDGene includes a longitudinal follow-up 
(LFU) component that collects data on participants once every 6 months using telephony and 
web-based surveys,24 this study uses data from the 21/October/2013 LFU dataset. This study 
presents results from the baseline visit and follow-up surveys capturing events and new 
comorbidities in 7080 participants who responded for each of the analysis variables and who 
did not report past physician diagnosis of diabetes or diabetes-associated medications 
(biguanides, thiazolidinediones and other drugs used to treat type 2 diabetes) at the baseline 
visit. Follow-up surveys in this group were queried for a new physician report of diabetes 
using the question “Have you been diagnosed with diabetes by a doctor?” and a new report 
of diabetes was considered an event (incident diabetes diagnosis) for this analysis.
Pulmonary function, FEV1, FVC and FEV1/FVC, were measured post-bronchodilator 
(albuterol) using the ndd EasyOne™ Spirometer and all tests were performed according to 
guidelines published by the American Thoracic Society.25 FEV1% predicted and FVC% 
predicted were used in models that did not include sex or ethnicity as these covariates are 
included in the sex and race-specific prediction equations.26 Quality of life was measured 
using the SGRQ which was obtained through participant self-report and overall and sub-
scores were calculated using the appropriate standard protocol.27 The mMRC scale was 
obtained from the COPDGene questionnaire. Smoking exposure (current versus former), 
smoking intensity (pack years), medication use, high cholesterol and high blood pressure 
were obtained through participant self-report.
Respiratory exacerbations in COPD patients are referred to as acute exacerbation of COPD 
(AECOPD) and represents a worsening of symptoms of COPD that require alteration of 
medications or hospitalization. As AECOPD is specific to patients with COPD we will use 
the more general term respiratory exacerbations to refer to lung infections in participants 
without COPD as well as AECOPD in participants with COPD. Respiratory exacerbations 
were captured as part of the telephony interview using a series of questions capturing both 
changes in symptomatology and management change;
• “Since we last talked have you had an episode of increased cough and 
phlegm or shortness of breath, which lasted 48 hours or more?
• Did you receive a new antibiotic?
• Did you receive any steroids either by pill or injection?
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• Did you go urgently to your doctor’s office?
• Did you go to an emergency room?
• Were you hospitalized?”
Respiratory exacerbation was recorded as Yes if the participant answered positively to 
receiving an antibiotic, steroid, urgent doctor’s visit, emergency room visit or hospitalization 
after reporting changes in symptomatology at any LFU contact for this analysis.
Statistical analyses were performed using the SAS system version 9.3 (Copyright (c) 2002–
2008 by SAS Institute Inc., Cary, North Carolina). We analyzed categorical data using χ2 
test for overall effects and by category using Kruskal-Wallis and continuous data using t 
tests (for normally distributed data) and transformed non-normally distributed data as 
appropriate and we considered a two-sided p value of α<0.05 to be statistically significant. 
Models were constructed using Cox Proportional Hazards models with time to event 
recorded as the time from the baseline visit until a physician diagnosis of diabetes, most 
recent contact via telephony or censoring due to all-cause mortality reported at the time of 
analysis. As a first step, a base model of incident diabetes diagnosis including known risk 
factors was fitted (sex, age, body mass index [BMI], smoking exposure, high cholesterol and 
high blood pressure) and these variables were retained in subsequent models. Additional 
pulmonary factors were added individually to this model to assess model improvement 
(FEV1%, FVC%, FEV1/FVC, SAE, chronic bronchitis, 6MWD, mMRC dyspnea score, 
corticosteroid use and GOLD category). Model fit was assessed comparing the reduction in 
−2 Log Likelihood with the addition of a pulmonary covariate distributed as chi-square with 
degrees of freedom contingent on the variable included.
Individuals who do not meet the GOLD criteria for COPD (FEV1/FVC<0.7) but who have 
impaired spirometry (FEV1<80%) are referred to as having preserved ratio with impaired 
spirometry (PRISm).28 All participants were placed into one of 3 categories; COPD (GOLD 
I–IV), PRISm or Control which includes all participants with neither COPD nor PRISm. 
FEV1% and FVC% are strongly collinear (Pearson Rho=0.79, p>=0.0001) and diabetes has 
been shown to have a stronger effect on FVC% than on FEV1%.5,11 We chose to exclude 
both FEV1% and FVC% from the stepwise selection that was used to assess the most 
parsimonious model of incident diabetes and instead undertook stepwise models including 
either FVC% or FEV1% separately.
Results
Incident diabetes was reported in 392 of 7080 participants during 21,519 person years of 
follow-up (mean follow-up time, 4.2 years). A total of 251 participants died and 15 
participants’ died after a report of incident diabetes. These participants follow-up time was 
truncated at their report of diabetes diagnosis. At the baseline visit, participants’ who went 
on to develop diabetes were more likely to be current smokers (p=0.02), had higher BMI and 
increased high blood pressure and high cholesterol (all comparisons p<0.0001), but were not 
different by gender, pack years of smoking history or age [Table 1]. Participants classified as 
PRISm were observed to have higher incidence of diabetes diagnosis [Figure 1].
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The base survival model of incident diabetes diagnosis included gender, age, smoking status, 
cumulative smoking exposure (pack years), high blood pressure, high cholesterol and BMI 
and this multivariable model agreed with the cross sectional results indicating that neither 
gender (p=0.5), cumulative smoking exposure (p=0.4) nor age (0.2) were significant 
predictors of diabetes [Table 2]. Subsequent models included these factors as potential 
confounders and precision variables. Significant predictors of incident diabetes diagnosis in 
the base model included current smoking status (hazard ratio [HR]=1.9, 95% confidence 
interval [CI] 1.5–2.4, p <0.0001), BMI (HR=1.09, 95% C.I. 1.07–1.10 for 1 unit difference), 
high blood pressure (HR=1.4, 95% CI 1.2–1.8, p=0.0009) and high cholesterol (HR=1.3, 
95% CI 1.1–1.6, p=0.0081).
Both FEV1% and FVC% were significantly associated with incident diabetes when added to 
the base model after controlling for other known risk factors (p=0.0004 and <0.0001 
respectively) though their ratio was not [Table 3]. Other pulmonary markers were also 
associated with incident diabetes; respiratory exacerbation during the follow-up period (HR 
1.62, 95% CI 1.23–2.08), lower 6MWD (HR 0.93, 95% CI 0.91–0.96), corticosteroid use at 
baseline both oral (HR 1.80, 95% CI 1.03–3.15) and inhaled (HR 1.81, 95% CI 1.28–2.55), 
and PRISm pattern of lung function (HR 1.62, 95% CI 1.46–2.61). Neither chronic 
bronchitis (HR 1.10, 95% CI 0.85–1.42), nor COPD (HR 1.21, 95% CI 0.95–1.55) were 
associated with incident diabetes in these models.
As this study represents only current and former smokers and over represents individuals 
with COPD compared to the general population, we explored respiratory exacerbation across 
GOLD stages and found that respiratory exacerbation occurred during the 4.2 years of 
follow-up at all levels of obstructive disease and also occurred in participants without COPD 
[Figure 2]. Participants with incident diabetes were at higher risk for respiratory 
exacerbation if they were PRISm (22% versus 10%, p<0.0001) or GOLD 0 (14% versus 5%, 
p=0.0006). Participants with COPD showed a significant increase in AECOPD only in 
GOLD III (45% versus 31%, p=0.04).
The most parsimonious model of incident diabetes assessed using stepwise selection of all 
pulmonary variables is presented in Table 4. In addition to the base model of known risk 
factors, respiratory exacerbation (HR=1.5, 95% CI 1.2–2.0, p=0.0009), reduced 6MWD 
(−100 feet; HR=0.94, 95% CI 0.91–0.97, p<0.0001) and PRISm (PRISm compared to 
GOLD 0; HR=1.7, 95% CI 1.3–2.2, p=0.0003) were selected into the model. COPD (GOLD 
stage I–IV) was not significantly associated with incident diabetes (HR=0.95, 95% CI 0.7–
1.2, p=0.7) nor were the other potential markers measured as part of the COPDGene study.
Discussion
We observe, in this longitudinal study of current and former smokers, that markers of 
pulmonary health, beyond those measured using pulmonary function tests, are predictive of 
incident diabetes. Reduced 6MWD, respiratory exacerbation and PRISm were found to be 
associated with incident diabetes after controlling for known risk factors. While FEV1 and 
FVC have been shown to be associated with incident diabetes in other populations, these 
studies were not able to assess other measures of pulmonary health such as 6MWD, 
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treatment for COPD with corticosteroids, dyspnea, respiratory exacerbation or specific types 
of lung disease such as PRISm or chronic bronchitis due to their study designs. We found, 
after accounting for the effects of these other important markers of pulmonary health, that 
neither FEV1, FVC, nor their ratio remained significant predictors of incident diabetes in 
this population. While the known risk markers for future diabetes (current smoking, BMI, 
hypertension and high cholesterol) all remained significant in the most parsimonious 
multivariable model, no direct measures of pulmonary function remained.
An indirect measure of pulmonary function, exercise tolerance measured by 6MWD, was a 
strong, independent predictor of new diabetes identification and may represent a better 
overall measure of integrative health status than measures based on spirometry. Respiratory 
exacerbation may represent a different aspect of pulmonary health: the lungs’ ability to 
defend against bacterial and viral infection which may be decreased with hyperglycemia and 
may be detected before diabetes diagnosis as respiratory exacerbation. PRISm pattern 
pulmonary function is associated with obesity and obesity is on the metabolic pathway 
leading to type 2 diabetes. This is likely reflected in the association between PRISm and 
incident diabetes even after controlling for BMI though it should be noted that including the 
PRISm comparison into the model with BMI does not alter the effect of BMI on incident 
diabetes. BMI is known to be a poor marker of total adiposity and body composition making 
its use difficult to interpret precisely as a predictor of incident diabetes.
The lack of association between COPD and incident diabetes may be partially explained by 
the strong effect of COPD on 6MWD. A potential effect of pre or undiagnosed diabetes on 
the lungs is through increased blood glucose and glucose non-enzymatically binding with 
collagen and elastin in lung parenchyma resulting in reduced lung elasticity and reduced 
6MWD due to restrictions in airflow. Therefore, obstructive pattern lung disease may not be 
an important, independent predictor of future diabetes once the result of that obstruction, 
measured by reduced 6MWD, is accounted for. This observation would also help explain 
why dyspnea is a strong predictor of incident diabetes on its own but no longer predictive 
after controlling for PRISm pattern lung disease as dyspnea may measure a reaction to sub-
optimal inflation in pre or undiagnosed diabetes. This would also hold true if increased 
glucose affected the innate immune system of the lung, increasing the risk of lung infection 
and subsequent functional degradation as hyperglycemia is known to be associated with 
other types of infection. Chronic bronchitis is not associated with incident diabetes but 
respiratory exacerbation is, after controlling for known risk factors, 6MWD and PRISm. 
This suggests that smokers without COPD may be at increased risk for viral or bacterial lung 
infection.
We observed a known pattern of factors predicting pre or undiagnosed diabetes in these adult 
current and former smokers where age, gender, current smoking status, BMI, high blood 
pressure and lipid abnormalities were predictive of diabetes diagnosis over our longitudinal 
follow-up and remained significant with the addition of novel pulmonary-associated 
markers.
We hypothesized that individuals with pre or unrecognized diabetes were at increased risk 
for lung infection and that in the context of current and former heavy smoking that risk 
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could be recognized as exacerbations of COPD or respiratory exacerbation in participants 
who do not have COPD. Surfactant-D is a member of the innate immune system found in 
the lungs which has been shown to be reduced in obesity and type 2 diabetes.29 Surfactant-D 
has been shown to be reduced in smokers30 and serum surfactant-D has been shown to be 
associated with exacerbations of COPD potentially due to increased lung permeability.31 
Recent studies have shown that high blood glucose also affects the innate immune system by 
reducing the activity of beta-defensins which act against viral infection but also act against 
bacterial and fungal infection and are observed playing a protective role in the lungs.32 
Kiselar et al observed laboratory evidence that hyperglycemia increases the production of 
methylgloxal and glyoxal which irreversibly adduct with human β-defensin-2, reducing its 
antimicrobial function33 making infection more likely during hyperglycemia. Hamilton et al 
reported data from the Freemantle Heart Study showing that participants with type 2 
diabetes were at double the risk for hospitalization due to any infection compared to controls 
without diabetes and that the most common reason for hospitalization was pneumonia 
(49.2%).34 A recent, large scale population based study using the Danish National Registry 
showed an association between antibiotic use and type 2 diabetes where antibiotic 
prescriptions were more likely to be filled in those with type 2 diabetes compared to controls 
(odds ratio [OR] 1.53, 95% CI 1.50–1.55) and this observation was found both 5 years prior 
to diagnosis and 5 years post diagnosis with diabetes.35 Our study found that serious 
pulmonary events (SPE)/AECOPD were significant predictors of incident diabetes lending 
weight to this biological pathway.
Potential weaknesses of this study include the use of baseline measurement of known 
predictors that could not be assessed during the LFU as this follow-up protocol included 
telephony or web contact only. Future follow-up visits in the COPDGene cohort will collect 
these predictors and assess their change over time. Diabetes diagnosis is self-reported in 
COPDGene and has not been evaluated using known biomarkers such as fasting glucose, 
oral glucose tolerance test or glycosylated hemoglobin (HbA1c). Baseline diabetes status 
was assessed using both self-report and recorded medication use and all participants 
reporting either were excluded from this incident study. Diabetes type was also not 
differentiated in COPDGene though the age structure of the study suggests that incident type 
1 diabetes would be rare and all participants with existing diabetes were excluded from this 
incident study. Future studies of diabetes in COPDGene should assess diabetes status using 
gold standard biomarker measurement. The observed differences in SPE in participants 
without COPD (GOLD 0 and PRISm) may be due to a diabetes diagnosis that occurred 
because of health care contact resulting from the SPE itself. Evaluation of participant 
hospitalizations is not currently performed as a part of the COPDGene study.
The results of this study are of particular interest to clinicians as they identify new markers 
of pre or undiagnosed diabetes. SPEs, especially in current or former smokers without 
COPD (GOLD 0 and PRISm), may represent an early shift in a patient’s glycemic control 
that affects susceptibility to lung infection. We have shown that SPEs are independently 
associated with incident diabetes in participants with PRISm, those with no functional 
impairment (GOLD 0) and those with COPD [Figure 2]. This may represent a population of 
current and former smokers preferentially affected by reduced innate immunity in their lungs 
due to poor glycemic control.
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Conclusions
SPEs, reduced exercise capacity as measured by 6MWD and the PRISm pattern lung 
function impairment are significant, previously unrecognized predictors of the development 
of diabetes among current and former heavy smokers. This cluster of indicators may aid 
clinicians in identifying and treating patients with pre- or undiagnosed diabetes. Future 
studies should ascertain whether treatment for hyperglycemia and insulin resistance can 
reduce the occurrence of lung infection in this population.
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COPDGene COPD Genetic Epidemiology
LFU longitudinal follow-up
FEV1 forced expiratory volume in 1 second
FVC forced vital capacity
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ASL airway surface liquid
mMRC modified Medical Research Council
AECOPD acute exacerbation of COPD
HR hazard ratio
CI confidence interval
OR odds ratio
References
1. Sandler M. Is the lung a ‘target organ’ in diabetes mellitus? Arch Int Med. 1990; 150(7):1385–1388. 
doi: http://dx.doi.org/10.1001/archinte.1990.00390190051006. [PubMed: 2196023] 
Kinney et al. Page 8
Chronic Obstr Pulm Dis. Author manuscript; available in PMC 2016 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Mirrakhimov A. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet 
symphony. Cardiovasc Diabetol. 2012; 11(1) doi: http://dx.doi.org/10.1186/1475-2840-11-132. 
3. Sandler M, Bunn AE, Stewart RI. Cross-section study of pulmonary function in patients with 
insulin-dependent diabetes mellitus. Am Rev Respir Dis. 1987; 135(1):223–229. [PubMed: 
3492160] 
4. Klein OL, Meltzer P, Carnethon M, Krishnan JA. Type II diabetes mellitus is associated with 
decreased measures of lung function in a clinical setting. Respir Med. 2011; 105(7):1095–1098. doi: 
http://dx.doi.org/10.1016/j.rmed.2011.03.010. [PubMed: 21450445] 
5. van den Borst B, Gosker HR, Zeegers MP, Schols AMWJ. Pulmonary function in diabetes: A 
metaanalysis. Chest. 2010; 138(2):393–406. doi: http://dx.doi.org/10.1378/chest.09-2622. [PubMed: 
20348195] 
6. Ford ES, Mannino DM. Prospective association between lung function and the incidence of 
diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic 
Follow-up Study. Diabetes Care. 2004; 27(12):2966–70. doi: http://dx.doi.org/10.2337/diacare.
27.12.2966. [PubMed: 15562215] 
7. Eriksson KF, Lindgarde F. Poor physical fitness, and impaired early insulin response but late 
hyperinsulinaemia, as predictors of NIDDM in middle-aged Swedish men. Diabetologia. 1996; 
39(5):573–579. doi: http://dx.doi.org/10.1007/BF00403304. [PubMed: 8739917] 
8. Engstrom G, Janzon L. Risk of developing diabetes is inversely related to lung function: a 
population-based cohort study. Diabet Med. 2002; 19(2):167–170. doi: http://dx.doi.org/10.1046/j.
1464-5491.2002.00652.x. [PubMed: 11874435] 
9. Barrett-Connor E, Frette C. NIDDM, impaired glucose tolerance, and pulmonary function in older 
adults. The Rancho Bernardo Study. Diabetes Care. 1996; 19(12):1441–1444. doi: http://dx.doi.org/
10.2337/diacare.19.12.1441. [PubMed: 8941481] 
10. Bauer TA, Reusch JEB, Levi M, Regensteiner JG. Skeletal muscle deoxygenation after the onset of 
moderate exercise suggests slowed microvascular blood flow kinetics in type 2 diabetes. Diabetes 
Care. 2007; 30(11):2880–2885. doi: http://dx.doi.org/10.2337/dc07-0843. [PubMed: 17675540] 
11. Kinney GL, Black-Shinn JL, Wan ES, et al. Pulmonary function reduction in diabetes with and 
without chronic obstructive pulmonary disease. Diabetes Care. 2014; 37(2):389–395. doi: http://
dx.doi.org/10.2337/dc13-1435. [PubMed: 24026562] 
12. Kalsi KK, Baker EH, Fraser O, et al. Glucose homeostasis across human airway epithelial cell 
monolayers: role of diffusion, transport and metabolism. Pflügers Arch. 2009; 457(5):1061–1070. 
doi: http://dx.doi.org/10.1007/s00424-008-0576-4. [PubMed: 18781323] 
13. Baker EH, Wood DM, Brennan AL, Clark N, Baines DL, Phillips BJ. Hyperglycaemia and 
pulmonary infection. Proc Nutr Soc. 2006; 65(3):227–35. doi: http://dx.doi.org/10.1079/
PNS2006499. [PubMed: 16923307] 
14. Baker EH, Bell D. Blood glucose: of emerging importance in COPD exacerbations. Thorax. 2009; 
64(10):830–832. doi: http://dx.doi.org/10.1136/thx.2009.118638. [PubMed: 19786710] 
15. Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schǿnheyder HC, Srensen HT. Diabetes, 
glycemic control, and risk of hospitalization with pneumonia: a population-based case-control 
study. Diabetes Care. 2008; 31(8):1541–1545. doi: http://dx.doi.org/10.2337/dc08-0138. [PubMed: 
18487479] 
16. Baker EH, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in 
patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. 
Thorax. 2006; 61(4):284–289. doi: http://dx.doi.org/10.1136/thx.2005.051029. [PubMed: 
16449265] 
17. Ilyas R, Wallis R, Soilleux EJ. High glucose disrupts oligosaccharide recognition function via 
competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. 
Immunobiology. 2011; 216(1–2):126–131. doi: http://dx.doi.org/10.1016/j.imbio.2010.06.002. 
[PubMed: 20674073] 
18. Reading PC, Allison J, Crouch EC, Anders EM. Increased susceptibility of diabetic mice to 
influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose? J 
Virol. 1998; 72(8):6884–6887. [PubMed: 9658139] 
Kinney et al. Page 9
Chronic Obstr Pulm Dis. Author manuscript; available in PMC 2016 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
19. Klein OL, Smith W, Tipping M, Peng J, Williams MV. Reduced diffusion lung capacity in patients 
with type 2 diabetes mellitus predicts hospitalization for pneumonia. Diabetes Res Clin Pract. 
2011; 92(1):e12–15. doi: http://dx.doi.org/10.1016/j.diabres.2010.12.012. [PubMed: 21237523] 
20. Wannamethee SG, Shaper AG, Perry IJ. Smoking as a modifiable risk factor for type 2 diabetes in 
middle-aged men. Diabetes Care. 2001; 24(9):1590–1595. doi: http://dx.doi.org/10.2337/diacare.
24.9.1590. [PubMed: 11522704] 
21. Wannamethee SG, Shaper AG, Whincup PH. Modifiable lifestyle factors and the metabolic 
syndrome in older men: Effects of lifestyle changes. J Am Geriatr Soc. 2006; 54(12):1909–1914. 
doi: http://dx.doi.org/10.1111/j.1532-5415.2006.00974.x. [PubMed: 17198498] 
22. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study 
design. COPD. 2010; 7(1):32–43. doi: http://dx.doi.org/10.3109/15412550903499522. [PubMed: 
20214461] 
23. Global initiative for chronic Obstructive Pulmonary Disease (GOLD). Global initiative for chronic 
Obstructive Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic 
Obstructive Pulmonary Disease, updated November, 2006. GOLD website. http://
wwwgoldcopdorg/uploads/users/files/GOLDReport2006_0122pdf. Published 2006. Accessed July 
23, 2016
24. Stewart JI, Moyle S, Crxiner GJ, et al. Automated telecommunication to obtain longitudinal 
follow-up in a multicenter cross-sectional COPD study. COPD. 2012; 9(5):466–472. doi: http://
dx.doi.org/10.3109/15412555.2012.690010. [PubMed: 22676387] 
25. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur 
Respir J. 2005; 26(1):153–161. doi: http://dx.doi.org/10.1183/09031936.05.00034505. [PubMed: 
15994402] 
26. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the 
general U.S. population. Am J Respir Crit Care Med. 1999; 159(1):179–187. doi: http://dx.doi.org/
10.1164/ajrccm.159.1.9712108. [PubMed: 9872837] 
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for 
chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992; 
14(6):1321–1327. doi: http://dx.doi.org/10.1164/ajrccm/145.6.1321. 
28. Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio 
impaired spirometry (PRISm) in COPDGene. Respir Res. 2014; 15:89. doi: http://dx.doi.org/
10.1186/s12931-014-0089-y. [PubMed: 25096860] 
29. Fernandez-Real JM, Valdes S, Manco M, et al. Surfactant protein d, a marker of lung innate 
immunity, is positively associated with insulin sensitivity. Diabetes Care. 2010; 33(4):847–53. doi: 
http://dx.doi.org/10.2337/dc09-0542. [PubMed: 20086254] 
30. More JM, et al. Smoking reduces surfactant protein D and phospholipids in patients with and 
without chronic obstructive pulmonary disease. BMC Pulm Med. 2010; 10:53. doi: http://
dx.doi.org/10.1186/1471-2466-10-53. [PubMed: 20973980] 
31. Shakoori TA, et al. Serum surfactant protein D during acute exacerbations of chronic obstructive 
pulmonary disease. Dis Markers. 2009; 27(6):287–294. doi: http://dx.doi.org/
10.1155/2009/759304. [PubMed: 20075511] 
32. Herr C, Shaykhiev R, Bals R. The role of cathelicidin and defensins in pulmonary inflammatory 
diseases. Expert Opin Biol Ther. 2007; 7(9):1449–61. doi: http://dx.doi.org/
10.1517/14712598.7.9.1449. [PubMed: 17727333] 
33. Kiselar JG, et al. Modification of beta-defensin-2 by dicarbonyls methylglyoxal and glyoxal 
inhibits antibacterial and chemotactic function in vitro. PLoS One. 2015; 10(8):e0130533. doi: 
http://dx.doi.org/10.1371/journal.pone.0130533. [PubMed: 26244639] 
34. Hamilton EJ, Martin N, Makepeace A, Sillars BA, Davis WA, Davis TME. Incidence and 
predictors of hospitalization for bacterial infection in community-based patients with type 2 
diabetes: the fremantle diabetes study. PLoS One. 2013; 8(3):e60502. doi: http://dx.doi.org/
10.1371/journal.pone.0060502. [PubMed: 23536910] 
35. Mikkelsen, KH.; Knop, Fk; Frost, M.; Hallas, J.; Pottegård, A. Use of antibiotics and risk of type 2 
diabetes: a population-based case-control study; J Clin Endocrinol Metab. 2015. p. c20152696doi: 
http://dx.doi.org/10.1210/jc.2015-2696
Kinney et al. Page 10
Chronic Obstr Pulm Dis. Author manuscript; available in PMC 2016 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Incident Diabetes by GOLD Classification of COPD
The Υ axis indicates the percentage of participants at each GOLD stage reporting incident 
diabetes. GOLD=Global initiative for chronic Obstructive Lung Disease; PRISm=preserved 
ratio with impaired spirometry
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Figure 2. Serious Pulmonary Events by Diabetes Status
Figure 2 shows the percentage of participants reporting at least one serious pulmonary event 
(SPE)/acute exacerbation of COPD over the follow-up period (average 4.2 years) of the 
study.
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Table 1
Characteristics of the COPDGene Cohort at Baseline Visit
Incident Diabetes (n=392) Controls (n=6688) p
Age (SD) 60.2 ± 9.0 60.3 ± 9.0 0.9
Pack Years Smoking (SD) 46.0 ± 26.2 43.4 ± 23.8 0.05
Current Smoking (%yes) 0.54 0.47 0.02
Gender (%m) 0.49 0.50 0.8
BMI 32.0 ± 6.9 28.2 ± 5.9 <0.0001
High Blood Pressure (%yes) 0.53 0.37 <0.0002
High Cholesterol (%yes) 0.48 0.38 <0.0003
Table 1 shows univariate comparisons of known risk factors for diabetes by incident diabetes status. BMI=body mass index; SD=standard deviation
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Table 2
Base Survival Model of Incident Diabetes
Hazard Ratio 95% Confidence Limits p
Age (10 years) 0.97 0.85 – 1.12 0.7
ATS Pack Years (10 years) 1.02 0.98 – 1.07 0.3
Current Smoking (yes) 1.91 1.52 – 2.39 <0.0001
Gender (m) 1.07 0.87 – 1.31 0.5
BMI (1 unit change) 1.09 1.07 – 1.10 <0.0001
High Blood Pressure (yes) 1.44 1.16 – 1.78 0.0009
High Cholesterol (yes) 1.33 1.08 – 1.64 0.008
Table 2 shows a Cox Proportional Hazards model including the known risk factors for incident diabetes collected by COPDGene. p-values <0.05 
have been highlighted in yellow.
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Table 3
Univariate Associations Between Proposed Pulmonary Markers and Incident Diabetes
Estimate Hazard Ratio 95% CI p
FEV1% (10% change) −0.008 0.92 0.88 – 0.97 0.0004
FVC% (10% change) −0.014 0.87 0.82 – 0.93 <0.0001
FEV1/FVC (0.1 unit change) −0.32 0.97 0.90 – 1.04 0.4
Serious Pulmonary Event 0.48 1.62 1.23 – 2.08 0.0002
Chronic Bronchitis 0.09 1.10 0.85 – 1.42 0.48
Distance Walked (100 feet) −0.0007 0.93 0.91 – 0.96 <0.0001
mMRC Dyspnea Score (0 vs 1) 0.26 1.30 0.95 – 1.79
0.0006
mMRC Dyspnea Score (0 vs 2 0.43 1.53 1.11 – 2.11
mMRC Dyspnea Score (0 vs 3) 0.48 1.61 1.20 – 2.15
mMRC Dyspnea Score (0 vs 4) 0.67 1.96 1.40 – 2.75
Oral Corticosteroid Use 0.059 1.80 1.03 – 3.15 0.04
Inhaled Corticosteroid Use 0.59 1.81 1.28 – 2.55 0.0008
PRISm 0.67 1.95 1.46 – 2.61
<0.0001
GOLD I–IV 0.19 1.21 0.95 – 1.55
Table 3 shows 10 models that include all variables from Model 1 (Table 2) plus each pulmonary associated variable in a separate model. P reported 
is for the association between each marker and incident diabetes, p-values <0.05 have been highlighted in yellow. CI=confidence interval; 
FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; mMRC=modified Medical Research Council; PRISm=preserved ratio 
with impaired spirometry; GOLD=Global initiative for chronic Obstructive Lung Disease
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Table 4
Final Survival Model of Incident Diabetes Including Pulmonary Measures
Hazard Ratio 95% CI p
Age (10 years) 0.97 0.8 – 1.1 0.7
ATS Pack Years (10 years) 1.0 0.96 – 1.05 0.8
Current Smoking (yes) 1.8 1.4 –2.3 <0.0001
Gender (m) 1.2 0.9 – 1.5 0.07
BMI (1 unit change) 1.1 1.1 – 1.1 <0.0001
High Blood Pressure (yes) 1.3 1.1 – 1.7 0.006
High Cholesterol (yes) 1.4 1.1 – 1.7 0.004
Exacerbation (yes) 1.5 1.2 – 2.0 0.0009
6 MWD (100 feet) 0.94 0.91 – 0.97 <0.0001
PRISm (versus GOLD 0) 1.7 1.3 – 2.2 0.0003
GOLD I–IV(versus GOLD 0) 0.95 0.7 – 1.2 0.7
Table 4 shows the results of stepwise selection including Model 1 and selecting from FEV1/FVC, SAE, chronic bronchitis, 6MWD, mMRC 
Dyspnea Score, corticosteroid use and GOLD classification. This selection was repeated adding FEV1 or FVC and the resulting models included 
identical variables. Neither FEV1 nor FVC were selected into this model, p-values <0.05 have been highlighted in yellow. ATS=American Thoracic 
Society; BMI=body mass index; 6MWD=6-minute walk distance; PRISm=preserved ratio with impaired spirometry; GOLD=Global initiative for 
chronic Obstructive Lung Disease; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; mMRC=modified Medical Research 
Council
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